(Q37518265)

20 August 2017

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma (English)

1 reference

20 August 2017

1 reference

Minesh P Mehta

21

0 references

Harold H Kim

17

object named as

Harold Kim

1 reference

20 August 2017

Jan C Buckner

1

1 reference

20 August 2017

Edward G Shaw

2

1 reference

20 August 2017

Stephanie L Pugh

3

1 reference

20 August 2017

Arnab Chakravarti

4

1 reference

20 August 2017

Mark R Gilbert

5

1 reference

20 August 2017

Geoffrey R Barger

6

1 reference

20 August 2017

Stephen Coons

7

1 reference

20 August 2017

Peter Ricci

8

1 reference

20 August 2017

Dennis Bullard

9

1 reference

20 August 2017

Paul D Brown

10

1 reference

20 August 2017

Keith Stelzer

11

1 reference

20 August 2017

David Brachman

12

1 reference

20 August 2017

John H Suh

13

1 reference

20 August 2017

Christopher J Schultz

14

1 reference

20 August 2017

Jean-Paul Bahary

15

1 reference

20 August 2017

Barbara J Fisher

16

1 reference

20 August 2017

Albert D Murtha

18

1 reference

20 August 2017

Erica H Bell

19

1 reference

20 August 2017

Minhee Won

20

1 reference

20 August 2017

Walter J Curran

22

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 April 2016

1 reference

The New England Journal of Medicine

20 August 2017

1 reference

20 August 2017

374

1 reference

20 August 2017

14

1 reference

20 August 2017

1344-1355

1 reference

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5170873

Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5170873

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5170873

Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5170873

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5170873

Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5170873

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5170873

Evaluation of survival data and two new rank order statistics arising in its consideration

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5170873

Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5170873

Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5170873

Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5170873

Low-grade oligodendroglioma responds to chemotherapy.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5170873

Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5170873

2 September 2018

Identifiers

DOI

10.1056/NEJMOA1500925

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

27050206

1 reference